CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer - Wikidata - wikimedia - TriplyDB

CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer

CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer

http://www.wikidata.org/entity/Q28473504

about

Cytotoxic and targeted therapy for hereditary cancers Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study Current perspectives on CHEK2 mutations in breast cancer.Chemosensitivity and p53; new tricks by an old dog Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.Identification of two poorly prognosed ovarian carcinoma subtypes associated with CHEK2 germ-line mutation and non-CHEK2 somatic mutation gene signatures.Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk.Are current development programs realising the full potential of new agents?TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy.Drug therapy for hereditary cancers Breast tumors from CHEK2 1100delC-mutation carriers: genomic landscape and clinical implications.Association of Germline CHEK2 Gene Variants with Risk and Prognosis of Non-Hodgkin Lymphoma Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers Response to DNA damage of CHEK2 missense mutations in familial breast cancer.Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.Microvessel density and status of p53 protein as potential prognostic factors for adjuvant anthracycline chemotherapy in retrospective analysis of early breast cancer patients group Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival Strength and weakness of phase I to IV trials, with an emphasis on translational aspects.Prevalence of the CHEK2 R95* germline mutation Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases Heterogeneous perivascular cell coverage affects breast cancer metastasis and response to chemotherapy Molecular basis for therapy resistance.P53 and its molecular basis to chemoresistance in breast cancer.Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers.The role of DNA damage responses in p53 biology.Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers.Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia.MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide.Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function.Effects of concomitant inactivation of p53 and pRb on response to doxorubicin treatment in breast cancer cell lines.Targeted sequencing of established and candidate colorectal cancer genes in the Colon Cancer Family Registry Cohort.Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity.Study on the Mechanism of Cell Cycle Checkpoint Kinase 2 (CHEK2) Gene Dysfunction in Chemotherapeutic Drug Resistance of Triple Negative Breast Cancer Cells.Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia.MYC-Induced miR-203b-3p and miR-203a-3p Control Bcl-xL Expression and Paclitaxel Sensitivity in Tumor Cells

P2860

Q26739366-EC0C4F4E-FBF1-41BD-B1D1-CA14AD83141A Q28743906-CE9D7780-294C-4EF3-9893-6DB0F6719632 Q33712610-5C96107C-03A6-46C3-8996-23693695F52B Q33739325-290E07AA-D772-41C6-859D-61AC1AD6AA13 Q33893910-EC2B6C17-1C5B-4985-A475-749BE53F099A Q33952816-31968715-F76E-4796-A980-2DDDAC932E1B Q34020037-ECBD5AA5-E8C3-4AF7-9F87-D611F4435994 Q34257381-1D71557D-190C-4F9D-9401-C82F2A108B28 Q34423576-FEB039EC-9F97-4E0E-B5DB-049FE81F12CC Q34576275-2DA54346-D46E-4A4A-8E61-A36AD53B3320 Q35208929-F84EF86F-2CFC-4D9A-AD46-84AA898EBE02 Q35683548-F8FC9A21-C124-457D-9323-70C29C13E2B4 Q35823280-D63E024F-36BD-4CB4-A7B3-1E948F178EA3 Q35977371-E041AF75-5C02-4ED6-91BF-5F069F019A81 Q35997577-B1CA554B-25FB-4EF9-9F18-BA02E5245F3B Q36245541-7560BC9D-A852-47B7-B48C-C8916CA578C9 Q36250209-B791CF1C-60D0-44EF-A00B-083FC745ED5C Q36924468-96F0A088-C1A0-4BFA-96E4-C92EAA737F51 Q37039810-F074FAE9-897A-486F-86E1-C8DDBA6E36D2 Q37291784-DDEAF03E-37F7-402E-A320-D47CFD715C54 Q37352557-2463A217-C333-4919-8560-7A78DBBC911F Q37509823-6262AFC1-56E9-48FA-8600-9A46748986B3 Q37751530-03E02E15-2CD9-4F0F-A7DE-B0F0D4AE7081 Q37982133-1CFB4214-B154-4EDC-BDAC-BEF69576AEEF Q38087850-2DF9C4CD-8D3B-4B27-8502-B9D3BC875984 Q38331206-80DD2866-6B5F-44AC-999B-0F2EC7AC700E Q38389226-1F0EEB93-0D1D-4452-9676-31C3C5273389 Q39446764-A3FCED79-12E0-40C2-9A29-5335F16F53C6 Q40320494-B75D2108-8F7E-41E6-B70F-17C2CE43A5FF Q40907746-43EC593F-892B-47D8-B1B1-C36B3083EBB9 Q41899812-CA0D1ECC-FB4E-4789-85A0-3AE92CAA110B Q42253633-A35DC215-6B22-4707-ABAC-360134F977CD Q46471388-A1C30FAD-2BAC-4E43-94DF-B7A44F578E21 Q49097031-E65CF16E-E397-4F09-A6D7-898CBEC4CFA6 Q54109834-FFC5E17F-E48C-4EE3-A674-54FAC4F2AC4F Q54566271-34D8AF3E-7F0D-4482-9DCA-7256926B91DF Q57805991-EF2B1407-F790-4217-8D64-21BD5A1DF26C

P2860

CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer

http://www.wikidata.org/entity/Q28473504

description

2008 nî lūn-bûn

@nan

2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

CHEK2 mutations affecting kina ...... bicin in primary breast cancer

@ast

CHEK2 mutations affecting kina ...... bicin in primary breast cancer

@en

CHEK2 mutations affecting kina ...... bicin in primary breast cancer

@nl

type

label

CHEK2 mutations affecting kina ...... bicin in primary breast cancer

@ast

CHEK2 mutations affecting kina ...... bicin in primary breast cancer

@en

CHEK2 mutations affecting kina ...... bicin in primary breast cancer

@nl

prefLabel

CHEK2 mutations affecting kina ...... bicin in primary breast cancer

@ast

CHEK2 mutations affecting kina ...... bicin in primary breast cancer

@en

CHEK2 mutations affecting kina ...... bicin in primary breast cancer

@nl

P1433

Q28473504-9CB4A78E-A77C-4CF4-8240-0AFEF00A8DDF

P1476

Q28473504-9A653971-F867-4C2F-94DE-3B92EA677675

P2093

Q28473504-0288406F-C03B-4152-A560-865B59F3C031

Q28473504-2F4E1CE7-3D7F-4B54-BA6C-7971896B6352

Q28473504-4B44F746-8762-43D0-94AA-4B30AC93C7F1

Q28473504-79DC8BBA-684A-4B2F-BB58-7975FCEE2531

Q28473504-7F643ED8-6034-4213-B5B0-EB0E8AC82F0E

Q28473504-867252F3-C2BE-4341-AFA3-296F3DFD43E0

Q28473504-BF7E5B7B-8F91-4909-8D74-94C969C65949

Q28473504-C2902384-ABB4-43A3-8EC1-C5DE69A11768

Q28473504-EDEB909B-1D5D-485E-8359-1404432B7DBB

Q28473504-F6BCFC99-FB6E-42E9-9A5A-D4E1B6704BE4

P2860

Q28473504-01E2D472-39C1-4CE8-B483-1B6A64C5FBF2

Q28473504-038DE82C-3ADF-480D-A724-310DECD9EC71

Q28473504-03F5A7D7-BEFB-4660-892E-C627E22C519F

Q28473504-086D3E06-A73B-4474-A1DA-B42AD20C680D

Q28473504-110C5B14-2A11-47BB-B796-655CF6A4702F

Q28473504-188FDF5C-3ACA-4B1C-A0A5-F5E412C7C7A0

Q28473504-199E13EB-062F-402B-A8C6-220AF580A734

Q28473504-1A553F63-7129-431D-AFB5-342599B3E686

Q28473504-1F32D951-0EE0-4743-8BB6-51FCD1645893

Q28473504-29035990-3B1B-47E6-898E-B3F47C0A1006

P304

Q28473504-6C4A15F6-A4C2-4CC0-9069-D7AE0EF76FB9

P31

Q28473504-3D4B67A7-50BF-46D2-A387-0710E8D02DE8

P3181

Q28473504-7AD41D2B-1CBB-43DC-A4CE-3DD9725F8834

P356

Q28473504-18C494EA-A591-476A-8FAD-CA3082FB3F1E

P407

Q28473504-79944045-E2B0-4496-A86A-94A2C0BC76E8

P433

Q28473504-FDB17EAF-EB59-41BB-BEF3-D4D1DE40F2F2

P478

Q28473504-13781186-3288-41E6-82BF-058476860F25

P50

Q28473504-7189224F-21CE-4082-9104-A04AF6426879

Q28473504-957FE71B-825E-4D0B-AFE7-34A151C728B8

Q28473504-DEADB84C-23FC-43FD-B366-7F0272C73B13

P577

Q28473504-CC018E8A-912B-456E-A7B3-84470398709F

P5875

Q28473504-68EC0195-FF0D-4478-8F83-3B5DD9DFE49C

P698

Q28473504-35157AFA-F515-45AA-937C-F30A9660C155

P932

Q28473504-A2A14D54-7D5F-479F-A741-E208A4E308C0

P3181

P356

JOURNAL.PONE.0003062

P1433

P1476

CHEK2 mutations affecting kina ...... bicin in primary breast cancer

@en

P2093

Bjørn Østenstad

http://www.w3.org/2001/XMLSchema#string

Elisabet O Berge

http://www.w3.org/2001/XMLSchema#string

Erik Løkkevik

http://www.w3.org/2001/XMLSchema#string

Gun Anker

http://www.w3.org/2001/XMLSchema#string

Ingvil Mjaaland

http://www.w3.org/2001/XMLSchema#string

Johan Richard Lillehaug

http://www.w3.org/2001/XMLSchema#string

Lars Fredrik Engebretsen

http://www.w3.org/2001/XMLSchema#string

Lovise Maehle

http://www.w3.org/2001/XMLSchema#string

Ranjan Chrisanthar

http://www.w3.org/2001/XMLSchema#string

Terje Risberg

http://www.w3.org/2001/XMLSchema#string

P2860

Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen

Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome

The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis

Chk2 activates E2F-1 in response to DNA damage

Chk2 regulates irradiation-induced, p53-mediated apoptosis in Drosophila

Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis

Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53

Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations

Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

P304

e3062

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3317090

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PONE.0003062

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Per Eystein Lønning

Stian Knappskog

Steinar Lundgren

P577

2008-08-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23192724

http://www.w3.org/2001/XMLSchema#string

P698

18725978

http://www.w3.org/2001/XMLSchema#string

P932

2518116

http://www.w3.org/2001/XMLSchema#string